BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 17270340)

  • 1. Tamoxifen as prophylaxis for prevention of gynaecomastia and breast pain associated with bicalutamide 150 mg monotherapy in patients with prostate cancer: a randomised, placebo-controlled, dose-response study.
    Fradet Y; Egerdie B; Andersen M; Tammela TL; Nachabe M; Armstrong J; Morris T; Navani S
    Eur Urol; 2007 Jul; 52(1):106-14. PubMed ID: 17270340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Editorial comment on: Tamoxifen as prophylaxis for prevention of gynaecomastia and breast pain associated with bicalutamide 150 mg monotherapy in patients with prostate cancer: a randomised, placebo-controlled, dose-response study.
    Van Poppel H
    Eur Urol; 2007 Jul; 52(1):115. PubMed ID: 17270341
    [No Abstract]   [Full Text] [Related]  

  • 3. An open, randomised, multicentre, phase 3 trial comparing the efficacy of two tamoxifen schedules in preventing gynaecomastia induced by bicalutamide monotherapy in prostate cancer patients.
    Bedognetti D; Rubagotti A; Conti G; Francesca F; De Cobelli O; Canclini L; Gallucci M; Aragona F; Di Tonno P; Cortellini P; Martorana G; Lapini A; Boccardo F
    Eur Urol; 2010 Feb; 57(2):238-45. PubMed ID: 19481335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer.
    Boccardo F; Rubagotti A; Battaglia M; Di Tonno P; Selvaggi FP; Conti G; Comeri G; Bertaccini A; Martorana G; Galassi P; Zattoni F; Macchiarella A; Siragusa A; Muscas G; Durand F; Potenzoni D; Manganelli A; Ferraris V; Montefiore F
    J Clin Oncol; 2005 Feb; 23(4):808-15. PubMed ID: 15681525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gynecomastia and breast pain induced by adjuvant therapy with bicalutamide after radical prostatectomy in patients with prostate cancer: the role of tamoxifen and radiotherapy.
    Di Lorenzo G; Perdonà S; De Placido S; D'Armiento M; Gallo A; Damiano R; Pingitore D; Gallo L; De Sio M; Autorino R
    J Urol; 2005 Dec; 174(6):2197-203. PubMed ID: 16280763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploratory study of drug plasma levels during bicalutamide 150 mg therapy co-administered with tamoxifen or anastrozole for prophylaxis of gynecomastia and breast pain in men with prostate cancer.
    Boccardo F; Rubagotti A; Conti G; Potenzoni D; Manganelli A; Del Monaco D
    Cancer Chemother Pharmacol; 2005 Oct; 56(4):415-20. PubMed ID: 15838655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention and management of bicalutamide-induced gynecomastia and breast pain: randomized endocrinologic and clinical studies with tamoxifen and anastrozole.
    Saltzstein D; Sieber P; Morris T; Gallo J
    Prostate Cancer Prostatic Dis; 2005; 8(1):75-83. PubMed ID: 15685254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of tamoxifen and radiotherapy for prevention and treatment of gynaecomastia and breast pain caused by bicalutamide in prostate cancer: a randomised controlled trial.
    Perdonà S; Autorino R; De Placido S; D'Armiento M; Gallo A; Damiano R; Pingitore D; Gallo L; De Sio M; Bianco AR; Di Lorenzo G
    Lancet Oncol; 2005 May; 6(5):295-300. PubMed ID: 15863377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of bicalutamide-induced breast events.
    Sieber PR
    Expert Rev Anticancer Ther; 2007 Dec; 7(12):1773-9. PubMed ID: 18062751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and tolerability of radiotherapy as treatment for bicalutamide-induced gynaecomastia and breast pain in prostate cancer.
    Van Poppel H; Tyrrell CJ; Haustermans K; Cangh PV; Keuppens F; Colombeau P; Morris T; Garside L
    Eur Urol; 2005 May; 47(5):587-92. PubMed ID: 15826748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration.
    Tyrrell CJ; Iversen P; Tammela T; Anderson J; Björk T; Kaisary AV; Morris T
    BJU Int; 2006 Sep; 98(3):563-72. PubMed ID: 16771791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized trial comparing tamoxifen therapy vs. tamoxifen prophylaxis in bicalutamide-induced gynecomastia.
    Serretta V; Altieri V; Morgia G; Nicolosi F; De Grande G; Mazza R; Melloni D; Allegro R; Ferraù F; Gebbia V
    Clin Genitourin Cancer; 2012 Sep; 10(3):174-9. PubMed ID: 22502790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow-up of 9.7 years.
    Iversen P; McLeod DG; See WA; Morris T; Armstrong J; Wirth MP;
    BJU Int; 2010 Apr; 105(8):1074-81. PubMed ID: 22129214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of tamoxifen in reducing bicalutamide-induced gynaecomastia and breast pain.
    Nuttall MC; Harris JP; Dawkins GP
    BJU Int; 2007 Feb; 99(2):243-4. PubMed ID: 17313420
    [No Abstract]   [Full Text] [Related]  

  • 15. Phase I-II trial of weekly bicalutamide in men with elevated prostate-specific antigen and negative prostate biopsies.
    Zanardi S; Puntoni M; Maffezzini M; Bandelloni R; Mori M; Argusti A; Campodonico F; Turbino L; Branchi D; Montironi R; Decensi A
    Cancer Prev Res (Phila); 2009 Apr; 2(4):377-84. PubMed ID: 19336728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prophylactic breast irradiation with a single dose of electron beam radiotherapy (10 Gy) significantly reduces the incidence of bicalutamide-induced gynecomastia.
    Tyrrell CJ; Payne H; Tammela TL; Bakke A; Lodding P; Goedhals L; Van Erps P; Boon T; Van De Beek C; Andersson SO; Morris T; Carroll K
    Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):476-83. PubMed ID: 15380582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dutasteride and bicalutamide in patients with hormone-refractory prostate cancer: the Therapy Assessed by Rising PSA (TARP) study rationale and design.
    Sartor O; Gomella LG; Gagnier P; Melich K; Dann R
    Can J Urol; 2009 Oct; 16(5):4806-12. PubMed ID: 19796455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is prophylactic breast radiotherapy necessary in all patients with prostate cancer and gynecomastia and/or breast pain?
    Ozen H; Akyol F; Toktas G; Eskicorapci S; Unluer E; Kuyumcuoglu U; Abay E; Cureklibatur I; Sengoz M; Yalcin V; Akpinar H; Zorlu F; Sengor F; Karaman I
    J Urol; 2010 Aug; 184(2):519-24. PubMed ID: 20620411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The bicalutamide 150 mg early prostate cancer program: findings of the North American trial at 7.7-year median followup.
    McLeod DG; See WA; Klimberg I; Gleason D; Chodak G; Montie J; Bernstein G; Morris C; Armstrong J
    J Urol; 2006 Jul; 176(1):75-80. PubMed ID: 16753373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Gynecomastia as a complication of hormonotherapy for prostate cancer: effect of prophylactic breast irradiation].
    Abdah-Bortnyak R; Bernstein Z; Ramon N; Zalman D; Shnaider J; Kuten A
    Harefuah; 2007 Feb; 146(2):126-8, 164-5. PubMed ID: 17352282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.